[CAS NO. 1445993-26-9] Mivebresib (ABBV-075)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1445993-26-9]
Store
Catalog
SLK-S8400
Brand
Selleck
CAS
1445993-26-9
DESCRIPTION [1445993-26-9]
Overview
| MDL | MFCD30377200 |
|---|---|
| Molecular Weight | 459.47 |
| Molecular Formula | C22H19F2N3O4S |
| SMILES | CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1764 mL | 10.8821 mL | 21.7642 mL |
| 5 mM | 0.4353 mL | 2.1764 mL | 4.3528 mL |
| 10 mM | 0.2176 mL | 1.0882 mL | 2.1764 mL |
| 50 mM | 0.0435 mL | 0.2176 mL | 0.4353 mL |
Description
Mivebresib (ABBV-075) is a novel inhibitor. It binds bromodomains of BRD2/4/T with similar affinities (Ki of 1-2.2 nM) and highly selective for 18 bromodomain proteins tested (Kd > 1 μM; more than 600-fold selectivity vs. BRD4), but exhibits roughly 10-fold weaker potency towards BRD3 (Ki of 12.2 nM) and has moderate activity towards CREBBP (Kd = 87 μM; 54-fold selectivity vs. BRD4). Mivebresib(ABBV-075) efficiently triggers in various tumor cell.
In vitro
ABBV-075 exhibits robust single agent activity in cell viability assays across cancer cell lines derived from solid tumors, leukemia and lymphomas. It could disrupt cell cycle control leading to G1 arrest followed by senescence, inhibit oncogenesis drivers leading to apoptosis, and potentially target tumor microenvironment to provide additional therapeutic benefit.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.